Tolero Pharmaceuticals Finds $14.2M

Salt Lake City, Utah-based Tolero Pharmaceuticals, a biopharmaceuticals firm which is targeting oncology and hematologic disease, has raised $14.2M in a Series B funding round. The company said the round was led by Fred Alger Management Inc., and also included other institutional and individual investors. Tolero's lead program is aimed at treating acute myeloid leukemia (AML). The company said the funds go towards further development and commercialization of the product. Tolero Pharmaceuticals is led by Dr. David Bearss. More information »